Pay with Crypto and get 10% off your order!
Expanded profile for AIDS monitoring and prognosis. An increase in activation markers is associated with poor prognosis.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Landay AL, Jessop C, Lennette ET, Levy JA. Chronic fatigue syndrome: Clinical condition associated with immune activation. Lancet. 1991 Sep 21; 338(8769):707-712. PubMed 1679864
Sadler D, Keren DF. Surface marker assays in immunodeficiency diseases. In: Keren DF, Hanson CA, Hurtubise PE, eds. Flow Cytometry and Clinical Diseases. Chicago, Ill: ASCP Press;1994:chap 9.
